BioNTech COO Sean Marett Reveals How To Spend $270M

12 Apr 2018

• By Mike Ward

BioNTech AG raised $270m in a series A venture round at the start of 2018 as it pursues an ambition to create a fully integrated biopharmaceutical company. COO Sean Marett tells Scrip how the funds will be invested.

Sean Marett, BioNTech COO • Source: BioNTech

BioNTech AG raised $270m in a series A venture round at the start of 2018 as it pursues an ambition to create a fully integrated biopharmaceutical company. During BIO-Europe Spring 2018, BioNTech COO Sean Marett told Scrip how the funds will be invested.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

All Over For iTeos But Applause For Plan To Return Cash Fast

29 May 2025

• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Sweden’s Hansa Slims Down Ahead of Key Readouts

27 May 2025

• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

End Is Nigh For 4SC After EMA’s No For Kinselby

21 May 2025

• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

20 May 2025

• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.